Skip to main content

NASDAQ:LVTX - Lava Therapeutics B.V. Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.67
  • Forecasted Upside: 83.04 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$12.93
▼ -1.02 (-7.31%)
1 month | 3 months | 12 months
Get New Lava Therapeutics B.V. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LVTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LVTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$23.67
▲ +83.04% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lava Therapeutics B.V. in the last 3 months. The average price target is $23.67, with a high forecast of $26.00 and a low forecast of $22.00. The average price target represents a 83.04% upside from the last price of $12.93.

Buy

The current consensus among 3 investment analysts is to buy stock in Lava Therapeutics B.V..

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2021SVB LeerinkInitiated CoverageOutperform$26.00Medium
i
Rating by D. Graybosch at SVB Leerink LLC
4/26/2021JPMorgan Chase & Co.Initiated CoverageOverweight$22.00N/A
i
4/26/2021Jefferies Financial GroupInitiated CoverageBuy$23.00N/A
i
4/19/2021JPMorgan Chase & Co.Initiated CoverageOverweight$22.00Low
i
4/19/2021Jefferies Financial GroupInitiated CoverageBuy$23.00Low
i
4/19/2021SVB LeerinkInitiated CoverageOutperform$26.00Low
i
Rating by D. Graybosch at SVB Leerink LLC
(Data available from 5/16/2016 forward)
Lava Therapeutics B.V. logo
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Read More

Today's Range

Now: $12.93
$12.55
$14.23

50 Day Range

MA: $13.43
$11.55
$16.00

52 Week Range

Now: $12.93
$9.76
$17.20

Volume

74,722 shs

Average Volume

99,238 shs

Market Capitalization

$327.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Lava Therapeutics B.V.?

The following sell-side analysts have issued research reports on Lava Therapeutics B.V. in the last twelve months: Jefferies Financial Group Inc., JPMorgan Chase & Co., and SVB Leerink LLC.
View the latest analyst ratings for LVTX.

What is the current price target for Lava Therapeutics B.V.?

3 Wall Street analysts have set twelve-month price targets for Lava Therapeutics B.V. in the last year. Their average twelve-month price target is $23.67, suggesting a possible upside of 83.0%. SVB Leerink LLC has the highest price target set, predicting LVTX will reach $26.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $22.00 for Lava Therapeutics B.V. in the next year.
View the latest price targets for LVTX.

What is the current consensus analyst rating for Lava Therapeutics B.V.?

Lava Therapeutics B.V. currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LVTX will outperform the market and that investors should add to their positions of Lava Therapeutics B.V..
View the latest ratings for LVTX.

What other companies compete with Lava Therapeutics B.V.?

How do I contact Lava Therapeutics B.V.'s investor relations team?

The company's listed phone number is 31 630 00 30 35. The official website for Lava Therapeutics B.V. is www.lavatherapeutics.com.